Af­ter back-to-back tri­al flops, Realm slash­es its staff, halts re­search work and pon­ders a fire sale

Just days af­ter re­port­ing its sec­ond mid-stage tri­al fail­ure in 5 months, lit­tle Realm Ther­a­peu­tics $RLM is throw­ing in the tow­el.

The Phase II fail­ure in atopic der­mati­tis — a crowd­ed field which in­cludes some no­table gi­ants — came on the heels of scrap­ping its Phase II pro­gram for PR013, a top­i­cal oph­thalmic so­lu­tion for the treat­ment of al­ler­gic con­junc­tivi­tis.

It was all too much for the in­vestors at the Malvern, PA biotech to swal­low. Mon­day morn­ing the biotech put out the word that it is aban­don­ing all clin­i­cal tri­al work and putting it­self up for sale, slash­ing its staff ros­ter in the process. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER